Intellia Therapeutics, Inc. reports clinical, regulatory and financing developments as a clinical-stage biopharmaceutical company using CRISPR gene editing and other core technologies. Its recurring updates center on in vivo and ex vivo therapeutic approaches for genetically defined diseases, including lonvoguran ziclumeran, or lonvo-z, for hereditary angioedema and nexiguran ziclumeran, or nex-z, for ATTR amyloidosis with cardiomyopathy and polyneuropathy.
Company announcements also cover Phase 3 clinical data, FDA interactions, biologics license application activity, quarterly financial results, common stock offerings, equity incentive grants and investor conference participation. These updates reflect Intellia's progress from gene-editing research and clinical development toward regulatory and commercial planning for its lead programs.
Intellia Therapeutics (NTLA) awarded inducement grants covering 12,900 common shares to new employees on November 1, 2026, as an employment incentive.
The grants to three employees consist of restricted stock units (RSUs), with one-third vesting annually over three years. Vesting requires continued service through each applicable vesting date. The compensation committee approved the awards under Nasdaq Listing Rule 5635(c)(4). They were granted outside stockholder-approved equity incentive plans under the amended 2024 Inducement Plan.
Intellia Therapeutics (Nasdaq: NTLA) reported third-quarter financial results as it prepares for a potential first-quarter 2027 launch of lonvo-z. The FDA accepted the hereditary angioedema treatment application for Priority Review, with a March 10, 2027 target decision date. Intellia completed deployment of its field organization; approval remains pending.
Enrollment finished in the MAGNITUDE-2 Phase 3 trial, exceeding the targeted randomization of 60 patients, while enrollment advanced in MAGNITUDE. Quarterly collaboration revenue fell to $7.163 million from $13.782 million, and net loss widened to $127.485 million from $101.324 million. Cash, equivalents and marketable securities totaled $614.807 million at September 30. Intellia expects existing resources to fund operations at least into 2028, excluding potential lonvo-z revenue and future loan funding. A senior secured term loan facility provides up to $400 million.
Intellia Therapeutics (Nasdaq: NTLA) completed enrollment in its Phase 3 MAGNITUDE-2 trial of nexiguran ziclumeran (nex-z) for hereditary transthyretin amyloidosis with polyneuropathy.
The randomized, double-blind, placebo-controlled trial was designed to evaluate efficacy and safety in approximately 60 patients. Adults were randomized 1:1 to a single 55 mg infusion of nex-z or placebo. The primary endpoints measure change in a modified score of nerve impairment at month 18 and change in blood transthyretin protein levels at day 29. Nex-z is an investigational gene-editing treatment designed to inactivate the TTR gene in the liver. It is also being evaluated in the Phase 3 MAGNITUDE trial for transthyretin amyloidosis with cardiomyopathy.
Intellia Therapeutics (Nasdaq: NTLA) will present Phase 1 nexiguran ziclumeran data at medical congresses on November 9 and November 18, 2026.
The American Heart Association presentation in Chicago will cover cardiac outcomes following a single dose, including patients with hereditary transthyretin amyloidosis with polyneuropathy, a disease affecting nerves, who also have cardiac involvement. The International Society of Amyloidosis presentation in Montevideo, Uruguay, will cover durability, outcomes and safety, with up to four years of follow-up in patients with the hereditary disease and polyneuropathy. Presentations will be available on Intellia’s Scientific Publications & Presentations webpage at the start of each session.
Intellia Therapeutics (NTLA) announced seven lonvoguran ziclumeran presentations at the ACAAI annual meeting taking place November 12–16, 2026, in Phoenix.
The two oral presentations will cover four-year follow-up after a one-time 50 mg dose and attack-free status without long-term preventive treatment in hereditary angioedema (HAE). Five posters will address patient experiences, quality of life, HAELO patient subgroups, preventive treatment patterns and an integrated analysis of Phase 1/2/3 studies. An investor webcast on November 12 at 10 a.m. ET will review presentation highlights and expert perspectives. Intellia also plans to discuss preparations for a planned commercial launch of lonvo-z in HAE.
Intellia Therapeutics (NTLA) awarded employment inducement equity grants to Executive Vice President and Chief Medical Officer Jing Marantz on October 26, 2026.
The awards comprise options to purchase 275,061 shares at an exercise price of $11.26 per share and restricted stock units covering 199,822 shares. The option exercise price equals the closing share price on the grant date. Both awards vest over three years, subject to continued employment or other service through each applicable vesting date. A majority of independent directors approved the grants under Nasdaq Listing Rule 5635(c)(4). They were issued outside stockholder-approved equity incentive plans under the amended 2024 Inducement Plan.
Intellia Therapeutics (NTLA) appointed Jing L. Marantz as Executive Vice President and Chief Medical Officer, effective October 26, 2026.
Marantz will lead the company’s translational, development, regulatory and medical affairs functions. She brings more than 25 years of biopharmaceutical industry experience and most recently served as Chief Medical Officer at Scholar Rock. Intellia plans to advance its Phase 3 clinical trials in transthyretin amyloidosis and expand its pipeline as it seeks to commercialize its first potential gene editing product that works inside the body.
Intellia Therapeutics (NTLA) awarded inducement grants covering 44,450 common shares to new employees on October 1, 2026, as an inducement to employment.
The time-based restricted stock units went to eight employees, with one-third vesting annually over three years. Vesting requires continued service through each applicable vesting date. The compensation committee approved the awards under Nasdaq Listing Rule 5635(c)(4). They were granted under the amended 2024 Inducement Plan, outside stockholder-approved equity incentive plans.
Intellia Therapeutics (NTLA) received FDA acceptance and Priority Review of its Biologics License Application for lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE), with a PDUFA target action date of March 10, 2027.
The FDA also advised that it is not currently planning to hold an advisory committee meeting on the application. Lonvo-z is positioned, if approved, to be the world’s first in vivo CRISPR-based therapy and the only one-time treatment for HAE. The BLA is supported by the global Phase 3 HAELO trial in 80 adults and adolescents (≥16 years) with Type 1 or Type 2 HAE, evaluating a single 50 mg dose.
HAELO met its primary and all key secondary endpoints, showing an 87% reduction in mean monthly attacks versus placebo from weeks 5 to 28 (p<0.0001). During the six-month efficacy period, 62% of lonvo-z patients were attack free and HAE-therapy free, versus 11% on placebo (p<0.0001). No serious adverse events occurred in the lonvo-z arm; all treatment emergent events were mild or moderate.
Intellia Therapeutics (NTLA) reported that on September 1, 2026 it granted inducement equity awards to 41 new employees under its 2024 Inducement Plan, as amended.
The awards consist of time-based restricted stock units covering an aggregate of 163,100 shares of common stock. One-third of each RSU award will vest annually over three years, subject to continued service with Intellia through each vesting date. These grants were made outside the stockholder-approved equity plans under the 2024 Inducement Plan, which was initially adopted by the board in June 2024, and were approved by the compensation committee as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).